SOPHARMA AD - Sales revenues for November

Spis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Spis załączników:

1. SFA_Sales_Revenues_November_2025_EN_espi.pdfSales revenues for November
   

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 266 / 2025

Date of issue: 2025-12-22

Short name of the issuer

SOPHARMA AD

Subject

Sales revenues for November

Official market - legal basis

Art. 56. 1. 2 of Act on Public Offering

Unofficial market - legal basis

Contents of the report:

Sofia, Bulgaria, December 22, 2025 – According to the requirements of Art. 100t of the Law on Public Offering of Securities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies, that for November 2025 the Company recorded increase in sales of 46% compared to the same month of the previous year, incl. 22% increase in domestic sales and 66% increase in export sales.
For the period since the beginning of 2025, the Company has achieved sales increase of 12%, including 2% increase in domestic sales and 19% increase in export sales.

Annexes

File Description

SFA_Sales_Revenues_November_2025_EN_espi.pdfSFA_Sales_Revenues_November_2025_EN_espi.pdf Sales revenues for November

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2025-12-22 Ognian Ivanov Donev Executive Director